Ranitidine does not affect psoriasis: A multicenter, double-blind, placebo-controlled study - 11/09/11

Doi : 10.1016/S0190-9622(97)80275-7

I.M. Zonneveld, MD ^a,^⁎, M.M.H.M. Meinardi, MD ^a, T. Karlsmark, MD ^b, U. Broby Johansen, MD ^b, G.R.R. Kuiters, MD ^c, L. Hamminga, MD ^c, B. Staberg, MD ^d, A.J. van't Veen, MD ^e, P.M.M. Bossuyt, PhD ^f, J.C.G. van Niel, PhD ^g, J.D. Bos, MD ^a
^a Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands
^b Department of Dermatology, Academic Medical Center, Rigshospitalet, Copenhagen, Denmark
^c Department of Dermatology, Academic Medical Center, Zwolle, The Netherlands
^d Department of Dermatology, Academic Medical Center, Roskildevej, Rødovre, Denmark
^e Academic Hospital, Erasmus University of Rotterdam, The Netherlands
^f Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
^g Medical Department, Glaxo B.V. Amsterdam, The Netherlands

^*Reprint requests: I. M. Zonneveld, MD, Dept. of Dermatology, Academisch Medisch Centrum, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Abstract

Background:

Data from open studies suggest that ranitidine has a beneficial effect on psoriasis and is well tolerated.

Objective:

Our purpose was to determine the effectiveness of ranitidine in a 24-week, multicenter, double-blind, placebo-controlled, dose-comparing study of 201 patients with psoriasis.

Methods:

Patients with moderate to severe psoriasis who had stopped systemic antipsoriatic therapy, including PUVA and UVB, for at least 10 weeks were included. After a washout period of 2 weeks, patients were randomly allocated to use either ranitidine, 150 mg twice a day; ranitidine, 300 mg twice a day; or placebo for up to 24 weeks. Assessment with the Psoriasis Area and Severity Index was performed at weeks 3, 6, 9, 12, 18, and 24 after randomization. Reduction of the Psoriasis Area and Severity Index score by 70% at the completion of the study was considered a treatment success.

Results:

The success rates at week 24 in the 300 mg, 600 mg, and placebo groups were 11 %, 5%, and 12%, respectively. No significant differences were observed between the three treatment groups at any stage of the study.

Conclusion:

This study provides strong evidence that ranitidine does not affect the skin disease in patients with psoriasis. Supported by Glaxo B. V., Zeist, The Netherlands.

Le texte complet de cet article est disponible en PDF.

Export

Vol 36 - N° 6

P. 932-934 - juin 1997 Retour au numéro

Article précédent

p53 tumor suppressor gene protein expression in premalignant and malignant skin lesions of kidney transplant recipients
Gillian E. Gibson, Anthony O'Grady, Elaine W. Kay, Mary Leader, Gillian M. Murphy

| Article suivant

Further evidence of the role of HLA-DR4 in the genetic susceptibility to actinic prurigo
Teresa Hojyo-Tomoka, Julio Granados, Gilberto Vargas-Alarcón, Jesús K. Yamamoto-Furusho, Elisa Vega-Memije, Roberto Cortós-Franco, Octavio Flores, Fernanda Teixeira, Luciano Domínguez-Soto

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Ranitidine does not affect psoriasis: A multicenter, double-blind, placebo-controlled study - 11/09/11

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL